Novartis to acquire Excellergy for $2bn upfront
The acquisition will provide access to the half-life extended, high-affinity anti-IgE antibody, Exl-111.
Drug Development
Simulations Plus and three pharma companies collaborate on AI-driven drug development
Cognito Therapeutics and Ochsner partner for new brain health approaches
Daiichi Sankyo and Tempus AI collaborate on ADC clinical development
Researchers become scientific tastemakers by handing more R&D to autonomous labs
Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis
MSD and Quotient collaborate on IBD drug targets
Monash University and ClinChoice partner on new therapies development
